REG - EKF Diagnostics Hldg - Additional Share Buyback Programme

EKF Diagnostics HoldingsAnnouncement

21/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU4949Ja&default-theme=true

RNS Number : 4949J  EKF Diagnostics Holdings PLC  21 May 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Additional Share Buyback Programme

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that following the successful conclusion of the initial
share buyback programme, confirmed on 13 May 2025, the Company intends to
conduct additional on-market purchases of ordinary shares of 1p each in the
Company ("Ordinary Shares") of up to a further c.£1.0m, pursuant to the
authorities obtained at the Company's last annual general meeting held on 20
May 2025. Any Ordinary Shares repurchased will be held in treasury.

 

Christopher Mills, Non-Executive Director of the Company, is the Chief
Investment Officer of Harwood Capital Management (Gibraltar) Limited
("Harwood"), which is investment manager to Oryx International Growth Fund
Limited ("Oryx") and Chief Investment Officer of North Atlantic Smaller
Companies Investment Trust PLC ("NASCIT"). Mr. Mills is a director and
shareholder in Oryx and also a director and shareholder in NASCIT. Oryx and
NASCIT hold 36,544,396 and 95,088,797 Ordinary Shares, respectively, and
132,433,193 Ordinary Shares in aggregate (with 800,000 Ordinary Shares held by
Harwood Capital LLP), which is equivalent to approximately 29.49% of the
current total voting rights in the Company. Harwood will facilitate the
participation of these entities in the share buy back pro rata to their
existing aggregate holding, with the intention that the aggregate indirect
beneficial interest of Mr. Mills remains at approximately this level and in
any event does not exceed 30.00% of the prevailing total voting rights in the
Company following any repurchases. This is solely in order for Mr. Mills and
the above connected entities (which are, unless otherwise established, deemed
to be acting in concert in accordance with the City Code on Takeovers and
Mergers) to avoid otherwise being subject to an obligation under the City Code
on Takeovers and Mergers to make a mandatory offer for the Company's entire
share capital or to obtain the requisite shareholder approval for a waiver
from the Takeover Panel from such obligation.

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

 

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Julian Baines, Executive Chair.

 

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
                                                                                           Tel: +44 (0)20 7496 3000

 Singer Capital Markets (Nominated Adviser & Broker)
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFSIEFIIFIE